![]() Results suggest that ERP is the dominant pricing method for in-patent pharmaceuticals. ![]() Comparative analysis of ERP systems across countries followed an analytical framework distilling ERP into twelve salient features, while ERP system performance was benchmarked against best practice principles across objectives and scope, administration and operations, methods used, and implementation. Primary and secondary evidence was used to inform our analysis. In this paper we outline and compare pharmaceutical pricing policies for in-patent prescription pharmaceuticals with emphasis on external reference pricing (ERP) in 11 countries across the Middle East and North Africa (MENA) region, and explore possible improvements in their pricing systems.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |